Biotech Stemline Therapeutics prices upsized IPO at $10, the low end of the range

By
A A A

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, raised $33 million by offering 3.3 million shares (1.0 million more than expected) at $10, the low end of the range of $10 to $12. Stemline Therapeutics plans to list on the NASDAQ under the symbol STML. Aegis Capital Corp. was the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: STML

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com